Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) Projected to Announce Earnings on Monday

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) will likely be announcing its results after the market closes on Monday, October 26th. Analysts expect the company to announce earnings of $0.13 per share and revenue of $1.11 billion for the quarter.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last released its earnings results on Monday, August 3rd. The company reported $0.36 earnings per share for the quarter, beating analysts’ consensus estimates of $0.18 by $0.18. The company had revenue of $1.04 billion during the quarter, compared to analyst estimates of $970.69 million. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 16.13% and a net margin of 46.67%. On average, analysts expect Shionogi & Co., Ltd. Unsponsored ADR to post $0.82 EPS for the current fiscal year and $0.79 EPS for the next fiscal year.

Shionogi & Co., Ltd. Unsponsored ADR Stock Performance

Shares of SGIOY stock opened at $9.61 on Friday. The business has a 50-day moving average of $9.13 and a 200 day moving average of $9.21. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.14 and a quick ratio of 1.00. Shionogi & Co., Ltd. Unsponsored ADR has a 1-year low of $7.83 and a 1-year high of $12.00. The stock has a market capitalization of $16.36 billion, a PE ratio of 9.61, a P/E/G ratio of 3.45 and a beta of 0.08.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on SGIOY. Zacks Research raised Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 15th. Jefferies Financial Group raised Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 14th. Three research analysts have rated the stock with a Strong Buy rating. According to data from MarketBeat.com, Shionogi & Co., Ltd. Unsponsored ADR presently has a consensus rating of “Strong Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. is a Japanese pharmaceutical company headquartered in Osaka, Japan. Founded in 1878, the company researches, develops, manufactures and markets prescription medicines, with a longstanding focus on infectious diseases and specialty therapies.

Its products and development programs have included Xofluza (baloxavir marboxil), an oral treatment for influenza; Fetroja (cefiderocol), an antibiotic for certain difficult-to-treat Gram-negative bacterial infections; and medicines for central nervous system disorders, pain and other therapeutic areas.